Pharmaceutical firm Pfizer has paid an undisclosed amount to purchase portfolio company Amplyx Pharmaceuticals, a US-based developer of anti-infective therapeutics.
Amplyx is developing drugs intended to combat invasive fungal infections. It announced positive topline results for its lead compound, Fosmanogepix (APX001), from phase 2 clinical trials in July 2020.
The purchase comes after Pfizer participated in a series C round for the company also featuring Lundbeckfonden Ventures, the strategic investment arm of pharmaceutical firm Liundbeck, that closed at $91.3m in May 2020.
The round was led by Sofinnova Investments and included life sciences real estate investment trust BioMed Realty’s BioMed Ventures unit, Adage Capital Management, 3×5 Partners, Arix Bioscience, New Enterprise Associates (NEA), Pappas Capital and RiverVest Venture Partners.
Amplyx had secured $1.5m in series A funding from investors including Golden Seeds, Life Science Angels and Tech Coast Angels in 2010 before adding $49.2m in a 2016 series B round backed by BioMed Ventures, 3×5 Partners, NEA and RiverVest Venture Partners.
